Finasteride is a synthetic compound classified as a 5-alpha reductase inhibitor. It is not produced endogenously but is manufactured for medical use. Chemically, it belongs to the class of azasteroids and is primarily used in the management of conditions related to dihydrotestosterone (DHT) levels. Researchers have extensively studied its effects in the context of hormone management, particularly in conditions like benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness). Finasteride's primary physiological role is to inhibit the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen involved in the development of male characteristics and conditions like prostate enlargement and hair loss. Researchers have found it effective in reducing prostate size and promoting hair regrowth in affected individuals. The mechanism of action of finasteride involves the selective inhibition of the type II 5-alpha reductase enzyme. This enzyme is responsible for converting testosterone into DHT, and its inhibition leads to decreased levels of DHT, thereby mitigating its effects on target tissues such as the prostate and hair follicles. Pharmacokinetically, finasteride has a half-life of approximately 5-6 hours. It is metabolized primarily in the liver and has an oral bioavailability of around 65%. Researchers have noted that its absorption is not significantly affected by food intake. Clinically, finasteride is used in the treatment of BPH and male pattern baldness. It is approved by regulatory agencies such as the FDA for these indications. The drug is generally well-tolerated, but researchers have observed potential side effects, including sexual dysfunction and mood changes. Its use is regulated and requires a prescription in many countries.